| Year |
Citation |
Score |
| 2022 |
Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, ... ... Rennie PS, et al. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. Nucleic Acids Research. PMID 36535377 DOI: 10.1093/nar/gkac1158 |
0.406 |
|
| 2022 |
Radaeva M, Li H, LeBlanc E, Dalal K, Ban F, Ciesielski F, Chow B, Morin H, Awrey S, Singh K, Rennie PS, Lallous N, Cherkasov A. Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors. Cells. 11. PMID 36139361 DOI: 10.3390/cells11182785 |
0.391 |
|
| 2021 |
Leblanc E, Ban F, Cavga AD, Lawn S, Huang CF, Mohan S, Chang MEK, Flory MR, Ghaidi F, Lingadahalli S, Chen G, Yu IPL, Morin H, Lallous N, Gleave ME, ... ... Rennie PS, et al. Development of 2-(5,6,7-Trifluoro-1-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. PMID 34661404 DOI: 10.1021/acs.jmedchem.1c00681 |
0.53 |
|
| 2021 |
Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh K, Gleave ME, Mohammed H, Rennie PS, Lack NA, Cherkasov A. Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. Cancers. 13. PMID 34298700 DOI: 10.3390/cancers13143488 |
0.538 |
|
| 2021 |
Pällmann N, Deng K, Livgård M, Tesikova M, Jin Y, Frengen NS, Kahraman N, Mokhlis H, Ozpolat B, Kildal W, Danielsen HE, Fazli L, Rennie PS, Banerjee PP, Üren A, et al. Stress mediated reprogramming of prostate cancer one-carbon cycle drives disease progression. Cancer Research. PMID 34183356 DOI: 10.1158/0008-5472.CAN-20-3956 |
0.394 |
|
| 2021 |
Radaeva M, Ban F, Zhang F, LeBlanc E, Lallous N, Rennie PS, Gleave ME, Cherkasov A. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. International Journal of Molecular Sciences. 22. PMID 33801338 DOI: 10.3390/ijms22052493 |
0.432 |
|
| 2020 |
Bafna D, Ban F, Rennie PS, Singh K, Cherkasov A. Computer-Aided Ligand Discovery for Estrogen Receptor Alpha. International Journal of Molecular Sciences. 21. PMID 32545494 DOI: 10.3390/Ijms21124193 |
0.427 |
|
| 2019 |
Snow O, Lallous N, Singh K, Lack N, Rennie P, Cherkasov A. Androgen receptor plasticity and its implications for prostate cancer therapy. Cancer Treatment Reviews. 81: 101871. PMID 31698174 DOI: 10.1016/J.Ctrv.2019.05.001 |
0.571 |
|
| 2019 |
Pällmann N, Livgård M, Tesikova M, Zeynep Nenseth H, Akkus E, Sikkeland J, Jin Y, Koc D, Kuzu OF, Pradhan M, Danielsen HE, Kahraman N, Mokhlis HM, Ozpolat B, Banerjee PP, ... ... Rennie PS, et al. Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene. PMID 31312022 DOI: 10.1038/S41388-019-0879-2 |
0.56 |
|
| 2019 |
Samudio I, Hofs E, Cho B, Li M, Bolduc K, Bu L, Liu G, Lam V, Rennie P, Jia W, Elisia I, Krystal G. UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 30933043 DOI: 10.1097/Cji.0000000000000261 |
0.417 |
|
| 2019 |
Hsing M, Wang Y, Rennie PS, Cox ME, Cherkasov A. ETS transcription factors as emerging drug targets in cancer. Medicinal Research Reviews. PMID 30927317 DOI: 10.1002/Med.21575 |
0.393 |
|
| 2019 |
Carabet LA, Leblanc E, Lallous N, Morin H, Ghaidi F, Lee J, Rennie PS, Cherkasov A. Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer. Molecules (Basel, Switzerland). 24. PMID 30791548 DOI: 10.3390/Molecules24040763 |
0.439 |
|
| 2019 |
Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications. 10: 323. PMID 30679434 DOI: 10.1038/S41467-018-08152-3 |
0.522 |
|
| 2019 |
Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer and Prostatic Diseases. 1: 289-296. PMID 12496869 DOI: 10.1038/Sj.Pcan.4500260 |
0.558 |
|
| 2018 |
Carabet LA, Rennie PS, Cherkasov A. Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches. International Journal of Molecular Sciences. 20. PMID 30597997 DOI: 10.3390/Ijms20010120 |
0.392 |
|
| 2018 |
Dueva E, Singh K, Kalyta A, LeBlanc E, Rennie PS, Cherkasov A. Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor. Molecules (Basel, Switzerland). 23. PMID 30441799 DOI: 10.3390/Molecules23112967 |
0.45 |
|
| 2018 |
Carabet LA, Lallous N, Leblanc E, Ban F, Morin H, Lawn S, Ghaidi F, Lee J, Mills IG, Gleave ME, Rennie PS, Cherkasov A. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. European Journal of Medicinal Chemistry. 160: 108-119. PMID 30326371 DOI: 10.1016/J.Ejmech.2018.09.023 |
0.51 |
|
| 2018 |
Dalal K, Morin H, Ban F, Shepherd A, Fernandez M, Tam KJ, Li H, LeBlanc E, Lack N, Prinz H, Rennie PS, Cherkasov A. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor. European Journal of Medicinal Chemistry. 157: 1164-1173. PMID 30193215 DOI: 10.1016/J.Ejmech.2018.08.059 |
0.557 |
|
| 2018 |
Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, et al. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Cancer Letters. PMID 30165195 DOI: 10.1016/J.Canlet.2018.08.016 |
0.584 |
|
| 2018 |
Ben-Eltriki M, Deb S, Hassona M, Meckling G, Fazli L, Chin MY, Lallous N, Yamazaki T, Jia W, Rennie PS, Cherkasov A, Tomlinson Guns ES. 20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors. Oncotarget. 9: 20965-20978. PMID 29765513 DOI: 10.18632/Oncotarget.24695 |
0.526 |
|
| 2018 |
Ban F, Dalal K, LeBlanc E, Morin H, Rennie PS, Cherkasov A. Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer. Molecular Informatics. PMID 29733509 DOI: 10.1002/Minf.201800043 |
0.568 |
|
| 2018 |
Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers. International Journal of Molecular Sciences. 19. PMID 29462880 DOI: 10.3390/Ijms19020579 |
0.411 |
|
| 2018 |
Lardizabal J, Ding J, Delwar Z, Rennie PS, Jia W. A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments. The Prostate. PMID 29450905 DOI: 10.1002/Pros.23490 |
0.509 |
|
| 2018 |
Morrissey C, Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Zhang X, Corey E, ... ... Rennie PS, et al. Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-Ia21 |
0.544 |
|
| 2017 |
Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Research. PMID 29118089 DOI: 10.1158/0008-5472.Can-17-0599 |
0.309 |
|
| 2017 |
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, ... ... Rennie PS, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 32: 474-489.e6. PMID 29017058 DOI: 10.1016/J.Ccell.2017.09.003 |
0.588 |
|
| 2017 |
Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, ... ... Rennie PS, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications. 8: 374. PMID 28851861 DOI: 10.1038/S41467-017-00393-Y |
0.613 |
|
| 2017 |
Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, Leblanc E, Gleave ME, ... ... Rennie PS, et al. Bypassing drug-resistance mechanisms of prostate cancer with small-molecules that target androgen receptor chromatin interactions. Molecular Cancer Therapeutics. PMID 28775145 DOI: 10.1158/1535-7163.Mct-17-0259 |
0.574 |
|
| 2017 |
Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, ... ... Rennie PS, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. PMID 28465491 DOI: 10.18632/Oncotarget.17124 |
0.561 |
|
| 2017 |
Ban F, Dalal K, Li H, LeBlanc E, Rennie PS, Cherkasov A. Best Practices of Computer-Aided Drug Discovery (CADD): Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action. Journal of Chemical Information and Modeling. PMID 28441481 DOI: 10.1021/Acs.Jcim.7B00137 |
0.344 |
|
| 2017 |
Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. Ebiomedicine. PMID 28412251 DOI: 10.1016/J.Ebiom.2017.04.006 |
0.533 |
|
| 2017 |
Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, ... ... Rennie PS, et al. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. European Urology. PMID 28408175 DOI: 10.1016/J.Eururo.2017.03.021 |
0.326 |
|
| 2017 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 292: 4359. PMID 28283588 DOI: 10.1074/Jbc.A117.553818 |
0.557 |
|
| 2017 |
Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A. Correction to Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor. Journal of Medicinal Chemistry. PMID 28118004 DOI: 10.1021/Acs.Jmedchem.7B00005 |
0.375 |
|
| 2017 |
Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, ... ... Rennie PS, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. PMID 28092670 DOI: 10.1038/Onc.2016.482 |
0.552 |
|
| 2017 |
Moniri MR, Hsing M, Rennie PS, Cherkasov A, Cox ME. The future of prostate cancer precision medicine: anti-ERG therapies Translational Cancer Research. 6. DOI: 10.21037/15472 |
0.551 |
|
| 2017 |
Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Lehman M, McPherson S, Roshan-Moniri M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Ross A, Karnes J, ... ... Rennie P, et al. Abstract 4908: Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastatic progression and patient mortality Cancer Research. 77: 4908-4908. DOI: 10.1158/1538-7445.Am2017-4908 |
0.547 |
|
| 2017 |
Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, ... ... Rennie PS, et al. Abstract 130: Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer Cancer Research. 77: 130-130. DOI: 10.1158/1538-7445.Am2017-130 |
0.49 |
|
| 2016 |
Lee JB, Zhang K, Tam YY, Quick J, Tam YK, Lin PJ, Chen S, Liu Y, Nair JK, Zlatev I, Rajeev KG, Manoharan M, Rennie PS, Cullis PR. A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Molecular Therapy. Nucleic Acids. 5: e348. PMID 28131285 DOI: 10.1038/Mtna.2016.43 |
0.524 |
|
| 2016 |
Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget. PMID 28038451 DOI: 10.18632/Oncotarget.14168 |
0.555 |
|
| 2016 |
Paul N, Carabet LA, Lallous N, Yamazaki T, Gleave ME, Rennie PS, Cherkasov A. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. Journal of Chemical Information and Modeling. 56: 2507-2516. PMID 28024400 DOI: 10.1021/Acs.Jcim.6B00400 |
0.496 |
|
| 2016 |
Lallous N, Leblanc E, Munuganti RS, Hassona MD, Al Nakouzi N, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, ... ... Rennie PS, et al. Targeting Binding Function-3 of the Androgen Receptor Blocks its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Molecular Cancer Therapeutics. PMID 27765852 DOI: 10.1158/1535-7163.Mct-16-0354 |
0.585 |
|
| 2016 |
Dalal K, Munuganti R, Morin H, Lallous N, Rennie PS, Cherkasov A. Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor. Methods in Molecular Biology (Clifton, N.J.). 1443: 31-54. PMID 27246333 DOI: 10.1007/978-1-4939-3724-0_4 |
0.5 |
|
| 2016 |
Delwar Z, Zhang K, Rennie PS, Jia W. Oncolytic virotherapy for urological cancers. Nature Reviews. Urology. PMID 27215429 DOI: 10.1038/Nrurol.2016.84 |
0.356 |
|
| 2016 |
Delwar ZM, Liu G, Kuo Y, Lee C, Bu L, Rennie PS, Jia WW. Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Oncotarget. PMID 27070093 DOI: 10.18632/Oncotarget.8637 |
0.354 |
|
| 2016 |
Hosseini-Beheshti E, Choi W, Weiswald LB, Kharmate G, Ghaffari M, Roshan-Moniri M, Hassona MD, Chan L, Chin MY, Tai IT, Rennie PS, Fazli L, Tomlinson Guns ES. Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment. Oncotarget. PMID 26840259 DOI: 10.18632/Oncotarget.7052 |
0.535 |
|
| 2016 |
Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology. 17: 10. PMID 26813233 DOI: 10.1186/S13059-015-0864-1 |
0.596 |
|
| 2016 |
Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, ... ... Rennie PS, et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute. 108. PMID 26657335 DOI: 10.1093/Jnci/Djv371 |
0.594 |
|
| 2016 |
Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients Genome Biology. DOI: 10.1186/s13059-015-0864-1 |
0.465 |
|
| 2016 |
Asim M, Zecchini H, Tarish F, Massie C, Baridi A, Warren A, Zhao W, McDuffus L, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment J, Lyons S, ... ... Rennie P, et al. Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-176 |
0.541 |
|
| 2016 |
Dalal K, Sharma A, Roshan-Moniri M, Borgmann H, Lallous N, Awrey S, Li H, Ban F, LeBlanc E, Cherkasov A, Rennie PS. Abstract 4644: Inhibition of the androgen receptor at two drug-targetable sites on the DNA-binding domain protein surface Cancer Research. 76: 4644-4644. DOI: 10.1158/1538-7445.Am2016-4644 |
0.596 |
|
| 2016 |
Tam KJ, Dalal K, Hsing M, Cheng CW, Chiang YT, Sharma A, Peacock JW, Cherkasov A, Wang Y, Gleave ME, Rennie PS, Ong CJ. Abstract 1834: Semaphorin 3C is an androgen receptor-regulated gene Cancer Research. 76: 1834-1834. DOI: 10.1158/1538-7445.Am2016-1834 |
0.376 |
|
| 2016 |
Li Y, Xie N, Gleave ME, Rennie P, Dong X. Abstract 1810: Heterogeneous activation of PP-1 and Akt determines AR-v7 protein expression in prostate cancer cells under AR inhibition Endocrinology. 76: 1810-1810. DOI: 10.1158/1538-7445.Am2016-1810 |
0.561 |
|
| 2016 |
Borgmann H, Dalal K, Beraldi E, Cherkasov A, Rennie P, Gleave M. 40 Efficacy of prostate cancer compound with novel mechanism of action targeting the DNA binding domain of the androgen receptor European Urology Supplements. 15: e40. DOI: 10.1016/S1569-9056(16)60042-8 |
0.55 |
|
| 2016 |
Borgmann H, Dalal K, Beraldi E, Cherkasov A, Rennie P, Gleave M. MP62-01 TARGETING THE DNA BINDING DOMAIN OF THE ANDROGEN RECEPTOR: EFFICACY OF PROSTATE CANCER COMPOUND WITH NOVEL MECHANISM OF ACTION Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.909 |
0.567 |
|
| 2015 |
Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, et al. Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget. PMID 26646591 DOI: 10.18632/Oncotarget.6479 |
0.522 |
|
| 2015 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 290: 25850. PMID 26500294 DOI: 10.1074/Jbc.A115.553818 |
0.557 |
|
| 2015 |
Li Y, Xie N, Gleave ME, Rennie PS, Dong X. AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget. PMID 26378044 DOI: 10.18632/Oncotarget.5608 |
0.519 |
|
| 2015 |
Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica E Nefrologica / Associazione Ricerche in Urologia. 87: 121-9. PMID 26150028 DOI: 10.4081/Aiua.2015.2.121 |
0.47 |
|
| 2015 |
Barfeld SJ, Fazli L, Persson M, Marjavaara L, Urbanucci A, Kaukoniemi KM, Rennie PS, Ceder Y, Chabes A, Visakorpi T, Mills IG. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget. 6: 12587-602. PMID 25869206 DOI: 10.18632/Oncotarget.3494 |
0.535 |
|
| 2015 |
Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Mills IG, Jin Y, Hotamisligil G, Saatcioglu F. Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. Embo Molecular Medicine. 7: 788-801. PMID 25864123 DOI: 10.15252/Emmm.201404509 |
0.604 |
|
| 2015 |
Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α. Breast Cancer Research : Bcr. 17: 27. PMID 25848700 DOI: 10.1186/S13058-015-0529-8 |
0.383 |
|
| 2015 |
Yu Y, Yang O, Fazli L, Rennie PS, Gleave ME, Dong X. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. The Prostate. 75: 1043-50. PMID 25833156 DOI: 10.1002/Pros.22988 |
0.606 |
|
| 2015 |
Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, et al. STAMP2 increases oxidative stress and is critical for prostate cancer. Embo Molecular Medicine. 7: 315-31. PMID 25680860 DOI: 10.15252/Emmm.201404181 |
0.563 |
|
| 2015 |
Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. International Journal of Cancer. Journal International Du Cancer. 136: E27-38. PMID 25138562 DOI: 10.1002/Ijc.29147 |
0.544 |
|
| 2015 |
Singh K, Munuganti RS, Butler M, Cherkasov A, Rennie PS. Abstract PD6-7: In-silico discovery of novel estrogen receptor-α inhibitors as potential therapeutics for tamoxifen resistant breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-7 |
0.419 |
|
| 2015 |
Munuganti RSN, Hassona MD, Leblanc E, Guns ET, Rennie PS, Cherkasov A. Abstract 3654: Targeting binding function-3 site on the androgen receptor to treat Enzalutamide-resistant prostate cancer Cancer Research. 75: 3654-3654. DOI: 10.1158/1538-7445.Am2015-3654 |
0.598 |
|
| 2015 |
Li H, Lallous N, Dalal K, Leblanc E, Ban F, Ciesielski F, Rennie PS, Cherkasov A. Abstract 3653: Structure-based study to overcome cross-reactivity of novel androgen receptor inhibitors Cancer Research. 75: 3653-3653. DOI: 10.1158/1538-7445.Am2015-3653 |
0.361 |
|
| 2015 |
Singh K, Munuganti RSN, Leblanc E, Cherkasov A, Rennie PS. Abstract 3651: The development of anti-estrogens targeting the activation function 2 site of estrogen receptor alpha for treatment of Tamoxifen resistant breast cancer Cancer Research. 75: 3651-3651. DOI: 10.1158/1538-7445.Am2015-3651 |
0.405 |
|
| 2015 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Guns ET, Cherkasov A, Rennie PS. Abstract 1778: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer Cancer Research. 75: 1778-1778. DOI: 10.1158/1538-7445.Am2015-1778 |
0.595 |
|
| 2015 |
Hassona MD, Chan LG, Meckling GR, Li H, LeBlanc E, Ban F, Cherkasov A, Rennie PS, Guns E. Abstract 1727: DNA-binding domain as an alternative target site on androgen receptor for prostate cancer therapy: Pre-clinicalin vivostudy of a novel small molecule for drug development Cancer Research. 75: 1727-1727. DOI: 10.1158/1538-7445.Am2015-1727 |
0.54 |
|
| 2015 |
Roshan-Moniri M, Hsing M, Butler MS, Lau D, Axerio-Cilies P, Yen P, Kim A, Lien S, Mroczek M, Ma D, Li H, Guo Y, Ban F, Ghaidi F, LeBlanc E, ... ... Rennie PS, et al. Abstract 1652: Therapeutic targeting of ETS factor ERG for the treatment of prostate cancer Cancer Research. 75: 1652-1652. DOI: 10.1158/1538-7445.Am2015-1652 |
0.608 |
|
| 2015 |
Butler MS, Hsing M, Moniri MR, Lau D, Yen P, Kim A, Lien S, Mroczek M, Ghaidi F, LeBlanc E, McIntosh L, Cox M, Cherkasov A, Rennie PS. Abstract 1648: Targeting ETS factor ETV4 as a novel therapeutic for the management of breast and prostate cancer Cancer Research. 75: 1648-1648. DOI: 10.1158/1538-7445.Am2015-1648 |
0.533 |
|
| 2014 |
Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, ... Rennie PS, et al. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chemistry & Biology. 21: 1476-85. PMID 25459660 DOI: 10.1016/J.Chembiol.2014.09.012 |
0.578 |
|
| 2014 |
Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treatment Reviews. 40: 1137-52. PMID 25455729 DOI: 10.1016/J.Ctrv.2014.10.005 |
0.541 |
|
| 2014 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 289: 26417-29. PMID 25086042 DOI: 10.1074/Jbc.M114.553818 |
0.6 |
|
| 2014 |
Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor Journal of Medicinal Chemistry. 57: 6458-6467. PMID 25062331 DOI: 10.1021/Jm500802J |
0.534 |
|
| 2014 |
Ban F, Leblanc E, Li H, Munuganti RSN, Frewin K, Rennie PS, Cherkasov A. Discovery of 1 H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3) Journal of Medicinal Chemistry. 57: 6867-6872. PMID 25025737 DOI: 10.1021/Jm500684R |
0.577 |
|
| 2014 |
Singh K, Munuganti RSN, Leblanc E, Cherkasov A, Rennie PS. Abstract 2521: Small molecule inhibitors targeting the activation function-2 site of estrogen receptor-α Cancer Research. 74: 2521-2521. DOI: 10.1158/1538-7445.Am2014-2521 |
0.445 |
|
| 2014 |
Munuganti RSN, Hassona MD, Leblanc E, Ban F, Guns ET, Rennie PS, Cherkasov A. Abstract 2508: The development of anti-androgens with a novel mechanism of action for treatment of castration-resistant prostate cancer Cancer Research. 74: 2508-2508. DOI: 10.1158/1538-7445.Am2014-2508 |
0.599 |
|
| 2014 |
Li H, Hassona MD, Lack NA, Axerio-Cilies P, Leblanc E, Guns ET, Rennie PS, Cherkasov A. Abstract 1632: Discovery of a novel series of androgen receptor antagonists with potential therapeutic applications in castration-resistant prostate cancer Cancer Research. 74: 1632-1632. DOI: 10.1158/1538-7445.Am2014-1632 |
0.604 |
|
| 2014 |
Dalal K, Li H, Moniri MR, Ban F, Sharma A, Cherkasov A, Rennie PS. Abstract 1235: Targeting the DNA binding domain of the androgen receptor as a potential therapy for prostate cancer Cancer Research. 74: 1235-1235. DOI: 10.1158/1538-7445.Am2014-1235 |
0.584 |
|
| 2014 |
Arnoldussen Y, Storm M, Sheng X, Tesikova M, Jin Y, Nenseth H, Zhao S, Mills I, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Hotamisligil G, Saatcioglu F. 495 Divergent androgen regulation of UPR pathways drives prostate cancer European Journal of Cancer. 50: 161. DOI: 10.1016/S0959-8049(14)70621-5 |
0.469 |
|
| 2013 |
Grosse L, Pâquet S, Caron P, Fazli L, Rennie PS, Bélanger A, Barbier O. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Research. 73: 6963-71. PMID 24121496 DOI: 10.1158/0008-5472.Can-13-1462 |
0.607 |
|
| 2013 |
Li H, Hassona MDH, Lack NA, Axerio-Cilies P, Leblanc E, Tavassoli P, Kanaan N, Frewin K, Singh K, Adomat H, Böhm KJ, Prinz H, Guns ET, Rennie PS, Cherkasov A. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer Molecular Cancer Therapeutics. 12: 2425-2435. PMID 23939374 DOI: 10.1158/1535-7163.Mct-13-0267 |
0.57 |
|
| 2013 |
Lallous N, Dalal K, Cherkasov A, Rennie PS. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. International Journal of Molecular Sciences. 14: 12496-519. PMID 23771019 DOI: 10.3390/Ijms140612496 |
0.625 |
|
| 2013 |
Moussavi M, Tearle H, Fazli L, Bell JC, Jia W, Rennie PS. Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus Molecular Therapy. 21: 842-848. PMID 23337981 DOI: 10.1038/Mt.2012.285 |
0.418 |
|
| 2013 |
Munuganti RSN, Leblanc E, Axerio-Cilies P, Labriere C, Frewin K, Singh K, Hassona MDH, Lack NA, Li H, Ban F, Tomlinson Guns E, Young R, Rennie PS, Cherkasov A. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives Journal of Medicinal Chemistry. 56: 1136-1148. PMID 23301637 DOI: 10.1021/Jm3015712 |
0.537 |
|
| 2013 |
Li H, Ren X, Leblanc E, Frewin K, Rennie PS, Cherkasov A. Identification of novel androgen receptor antagonists using structure- and ligand-based methods Journal of Chemical Information and Modeling. 53: 123-130. PMID 23278403 DOI: 10.1021/Ci300514V |
0.527 |
|
| 2013 |
Cao B, Liu X, Li J, Liu S, Qi Y, Xiong Z, Zhang A, Wiese T, Fu X, Gu J, Rennie PS, Sartor O, Lee BR, Ip C, Zhao L, et al. 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. International Journal of Cancer. Journal International Du Cancer. 132: 1277-87. PMID 22907191 DOI: 10.1002/Ijc.27754 |
0.616 |
|
| 2013 |
Munuganti R, Ban F, Li H, LeBlanc E, Axerio P, Frewin K, Guns ET, Cherkasov A, Rennie PS. Abstract 1070: New potent inhibitors of the androgen receptor that target its BF3 surface binding site. Endocrinology. 73: 1070-1070. DOI: 10.1158/1538-7445.Am2013-1070 |
0.385 |
|
| 2013 |
asim M, Massie C, Zecchini H, Baridi A, Gomes N, Mohammed H, Zecchini V, Madhu B, Qureshi A, Russell R, Hessenkemper W, Sriranjan R, Yang C, Lynch A, Gregorengko E, ... ... Rennie P, et al. Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B133 |
0.594 |
|
| 2012 |
So A, Rennie PS, Jia W. Intravesical oncoviral therapy for bladder cancer. The Journal of Urology. 188: 2039-40. PMID 23083873 DOI: 10.1016/J.Juro.2012.09.044 |
0.34 |
|
| 2012 |
Khatamianfar V, Valiyeva F, Rennie PS, Lu WY, Yang BB, Bauman GS, Moussa M, Xuan JW. TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. Bmj Open. 2. PMID 23048060 DOI: 10.1136/Bmjopen-2012-001410 |
0.472 |
|
| 2012 |
Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Human Molecular Genetics. 21: 3112-27. PMID 22505583 DOI: 10.1093/Hmg/Dds139 |
0.433 |
|
| 2012 |
Pâquet S, Fazli L, Grosse L, Verreault M, Têtu B, Rennie PS, Bélanger A, Barbier O. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression. The Journal of Clinical Endocrinology and Metabolism. 97: E428-32. PMID 22170718 DOI: 10.1210/Jc.2011-2064 |
0.548 |
|
| 2012 |
Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. International Journal of Cancer. Journal International Du Cancer. 131: E781-90. PMID 22095615 DOI: 10.1002/Ijc.27361 |
0.548 |
|
| 2012 |
Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. The Prostate. 72: 875-85. PMID 22072572 DOI: 10.1002/Pros.21490 |
0.546 |
|
| 2012 |
Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausió J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Letters. 315: 38-47. PMID 22055461 DOI: 10.1016/J.Canlet.2011.10.003 |
0.563 |
|
| 2012 |
Moussavi M, Moshgabadi N, Fazli L, Leblanc E, Zhang K, Jia W, Rennie PS. Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN -/- transgenic mice Cancer Gene Therapy. 19: 19-29. PMID 21921943 DOI: 10.1038/Cgt.2011.62 |
0.528 |
|
| 2012 |
Wafa LA, Cheng H, Plaa N, Ghaidi F, Fukumoto T, Fazli L, Gleave ME, Cox ME, Rennie PS. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. International Journal of Cancer. Journal International Du Cancer. 130: 2835-44. PMID 21780103 DOI: 10.1002/Ijc.26287 |
0.593 |
|
| 2012 |
Wong J, Lee C, Zhang K, Rennie PS, Jia W. Targeted oncolytic herpes simplex viruses for aggressive cancers. Current Pharmaceutical Biotechnology. 13: 1786-94. PMID 21740360 DOI: 10.2174/138920112800958751 |
0.33 |
|
| 2012 |
Zhang KX, Lee JB, Tam YYC, Tam YK, Cullis PR, Rennie PS. Abstract 1970: Liposomal nanoparticle siRNA delivery systems forin vivosilencing of the androgen receptor in human prostate cancer Cancer Research. 72: 1970-1970. DOI: 10.1158/1538-7445.Am2012-1970 |
0.577 |
|
| 2012 |
Thomas C, Wafa L, Lamoureux F, Cheng H, Fazli L, Gleave M, Rennie P. 236 The combination of carbidopa plus bicalutamide suppresses androgen-receptor transactivation, induces apoptosis and delays castration-resistant prostate cancer progression European Urology Supplements. 11: e236. DOI: 10.1016/S1569-9056(12)60233-4 |
0.56 |
|
| 2012 |
Perletti G, Magri V, Marras E, Monti E, Rennie PS, Trinchieri A. Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd009998 |
0.459 |
|
| 2011 |
Zhang KX, Firus J, Prieur B, Jia W, Rennie PS. To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers. 3: 1498-512. PMID 24212771 DOI: 10.3390/Cancers3021498 |
0.558 |
|
| 2011 |
Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. Journal of Medicinal Chemistry. 54: 8563-73. PMID 22047606 DOI: 10.1021/Jm201098N |
0.544 |
|
| 2011 |
Axerio-Cilies P, Lack NA, Nayana MRS, Chan KH, Yeung A, Leblanc E, Guns EST, Rennie PS, Cherkasov A. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening Journal of Medicinal Chemistry. 54: 6197-6205. PMID 21846139 DOI: 10.1021/Jm200532B |
0.554 |
|
| 2011 |
Cheng H, Leblanc E, Rennie PS. In vitro and in vivo silencing of the androgen receptor Methods in Molecular Biology. 776: 95-112. PMID 21796523 DOI: 10.1007/978-1-61779-243-4_7 |
0.611 |
|
| 2011 |
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, ... ... Rennie PS, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The Embo Journal. 30: 2719-33. PMID 21602788 DOI: 10.1038/Emboj.2011.158 |
0.587 |
|
| 2011 |
Liu L, Xie N, Rennie P, Challis JR, Gleave M, Lye SJ, Dong X. Consensus PP1 binding motifs regulate transcriptional corepression and alternative RNA splicing activities of the steroid receptor coregulators, p54nrb and PSF. Molecular Endocrinology (Baltimore, Md.). 25: 1197-210. PMID 21566083 DOI: 10.1210/Me.2010-0517 |
0.315 |
|
| 2011 |
Zhang KX, Kim C, Chow E, Chen IS, Jia W, Rennie PS. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2. Breast Cancer Research and Treatment. 125: 89-97. PMID 20232140 DOI: 10.1007/S10549-010-0828-9 |
0.371 |
|
| 2011 |
Cao B, Liu X, Li J, Xiong Z, Wiese T, Cheng H, Rennie PS, Zhao L, Zhang H, Dong Y. Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor Cancer Research. 71: 5561-5561. DOI: 10.1158/1538-7445.Am2011-5561 |
0.625 |
|
| 2011 |
Skinner LA, Zhang K, Jia W, Rennie P, So A. Abstract 2724: Intravesical treatment with Vesicular Stomatitis virus decreases the size of bladder tumors without adversely affecting the health and well-being of immune-competent mice Cancer Research. 71: 2724-2724. DOI: 10.1158/1538-7445.Am2011-2724 |
0.306 |
|
| 2011 |
Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A. Correction to Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening Journal of Medicinal Chemistry. 55: 565-565. DOI: 10.1021/Jm201689Y |
0.369 |
|
| 2011 |
Thomas C, Wafa L, Lamoureux F, Fazli L, Rennie P, Gleave M. MP-03.04 The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug Urology. 78: S41-S42. DOI: 10.1016/J.Urology.2011.07.053 |
0.514 |
|
| 2011 |
Matsui Y, Zhang K, Lee C, Skinner L, Banani J, So A, Rennie P, Jia W. 1352 MICRORNA-MEDIATED TARGETING OF ONCOLYTIC HERPES SIMPLEX VIRUS-1 TO HIGH-RISK BLADDER CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1174 |
0.323 |
|
| 2010 |
Zhang KX, Jia W, Rennie PS. Bioengineered viral vectors for targeting and killing prostate cancer cells. Bioengineered Bugs. 1: 92-6. PMID 21326934 DOI: 10.4161/Bbug.1.2.11102 |
0.559 |
|
| 2010 |
Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Molecular Cancer Therapeutics. 9: 2016-25. PMID 20571066 DOI: 10.1158/1535-7163.Mct-09-0924 |
0.61 |
|
| 2010 |
Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave M, Snoek R, Rennie PS. TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. Molecular Endocrinology (Baltimore, Md.). 24: 696-708. PMID 20181722 DOI: 10.1210/Me.2009-0229 |
0.579 |
|
| 2010 |
Lee CY, Bu LX, DeBenedetti A, Williams BJ, Rennie PS, Jia WW. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 929-35. PMID 20179676 DOI: 10.1038/Mt.2010.26 |
0.489 |
|
| 2010 |
Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, Ong C, Jia W, Rennie PS. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Research. 70: 1367-76. PMID 20145134 DOI: 10.1158/0008-5472.Can-09-2377 |
0.463 |
|
| 2010 |
Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Molecular Cancer Research : McR. 8: 119-30. PMID 20068069 DOI: 10.1158/1541-7786.Mcr-09-0277 |
0.534 |
|
| 2010 |
Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death International Journal of Cancer. 127: 830-838. PMID 19957332 DOI: 10.1002/Ijc.25088 |
0.412 |
|
| 2010 |
Zhang K, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS. Abstract 596: Oncolytic vesicular stomatitis virus selectively kills bladder cancer cells which have a low level of type I interferon receptor Cancer Research. 70: 596-596. DOI: 10.1158/1538-7445.Am10-596 |
0.378 |
|
| 2010 |
Moussavi M, Fazli L, Tearle H, Cox ME, Bell JC, Ong C, Jia W, Rennie PS. Abstract 2591: Differential oncolysis by vesicular stomatitis virus in prostate cancers arising in transgenic mice Cancer Research. 70: 2591-2591. DOI: 10.1158/1538-7445.Am10-2591 |
0.515 |
|
| 2010 |
Massie C, Lynch A, Stark R, Ramos-Montoya A, Fazli L, Warren A, Scott H, Bon H, Sharma N, Zecchini V, Matthews N, Osborne M, Hadfield J, Swatton J, McArthur S, ... ... Rennie P, et al. Abstract 1714: Transcriptional networks downstream of the AR identify clinically relevant prostate cancer targets Cancer Research. 70: 1714-1714. DOI: 10.1158/1538-7445.Am10-1714 |
0.554 |
|
| 2010 |
Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Cheng H, Rennie PS, Zhang H, Dong Y. Abstract 1708: Telomerase as an important target of androgen-signaling blockade for prostate cancer treatment Cancer Research. 70: 1708-1708. DOI: 10.1158/1538-7445.Am10-1708 |
0.542 |
|
| 2009 |
Lee CY, Rennie PS, Jia WW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5126-35. PMID 19671871 DOI: 10.1158/1078-0432.Ccr-09-0051 |
0.456 |
|
| 2009 |
Hahn S, Nesslinger NJ, Drapala RJ, Bowden M, Rennie PS, Pai HH, Ludgate C, Nelson BH. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. International Journal of Cancer. 125: 2871-8. PMID 19554630 DOI: 10.1002/Ijc.24673 |
0.335 |
|
| 2009 |
Dong X, Yu C, Shynlova O, Challis JR, Rennie PS, Lye SJ. p54nrb is a transcriptional corepressor of the progesterone receptor that modulates transcription of the labor-associated gene, connexin 43 (Gja1). Molecular Endocrinology (Baltimore, Md.). 23: 1147-60. PMID 19423654 DOI: 10.1210/Me.2008-0357 |
0.374 |
|
| 2009 |
Zhang KX, Moussavi M, Kim C, Chow E, Chen IS, Fazli L, Jia W, Rennie PS. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells. Cancer Gene Therapy. 16: 820-31. PMID 19373278 DOI: 10.1038/cgt.2009.28 |
0.497 |
|
| 2009 |
Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 39-47. PMID 19118031 DOI: 10.1158/1078-0432.Ccr-08-1726 |
0.551 |
|
| 2008 |
Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Research. 68: 4506-10. PMID 18559493 DOI: 10.1158/0008-5472.Can-08-0238 |
0.372 |
|
| 2007 |
Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research. 67: 10455-65. PMID 17974989 DOI: 10.1158/0008-5472.Can-07-2057 |
0.571 |
|
| 2007 |
Read JT, Rahmani M, Boroomand S, Allahverdian S, McManus BM, Rennie PS. Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. The Journal of Biological Chemistry. 282: 31954-63. PMID 17728259 DOI: 10.1074/Jbc.M702099200 |
0.601 |
|
| 2007 |
Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Molecular Cancer. 6: 38. PMID 17553164 DOI: 10.1186/1476-4598-6-38 |
0.621 |
|
| 2007 |
Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Research. 67: 4630-7. PMID 17510388 DOI: 10.1158/0008-5472.Can-06-4556 |
0.623 |
|
| 2007 |
Lee CY, Bu LX, Rennie PS, Jia WW. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Therapy. 14: 652-60. PMID 17479106 DOI: 10.1038/Sj.Cgt.7701052 |
0.515 |
|
| 2007 |
Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. The Prostate. 67: 1038-52. PMID 17455228 DOI: 10.1002/Pros.20601 |
0.56 |
|
| 2007 |
Ivanov NI, Cowell SP, Brown P, Rennie PS, Guns ES, Cox ME. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clinical Nutrition (Edinburgh, Scotland). 26: 252-63. PMID 17337101 DOI: 10.1016/J.Clnu.2007.01.002 |
0.519 |
|
| 2007 |
Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH. Standard treatments induce antigen-specific immune responses in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1493-502. PMID 17332294 DOI: 10.1158/1078-0432.Ccr-06-1772 |
0.474 |
|
| 2007 |
Maffey AH, Ishibashi T, He C, Wang X, White AR, Hendy SC, Nelson CC, Rennie PS, Ausió J. Probasin promoter assembles into a strongly positioned nucleosome that permits androgen receptor binding. Molecular and Cellular Endocrinology. 268: 10-9. PMID 17316977 DOI: 10.1016/J.Mce.2007.01.009 |
0.459 |
|
| 2007 |
Tavassoli P, Snoek R, Ray M, Rao LG, Rennie PS. Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells. The Prostate. 67: 416-26. PMID 17219378 DOI: 10.1002/Pros.20532 |
0.549 |
|
| 2007 |
Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Human Pathology. 38: 161-70. PMID 16997353 DOI: 10.1016/J.Humpath.2006.07.003 |
0.58 |
|
| 2006 |
Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression Cancer Research. 66: 10613-10620. PMID 17079486 DOI: 10.1158/0008-5472.Can-06-0028 |
0.586 |
|
| 2006 |
Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. International Journal of Cancer. 118: 1108-19. PMID 16161052 DOI: 10.1002/Ijc.21469 |
0.617 |
|
| 2006 |
Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Therapy. 13: 32-43. PMID 16052226 DOI: 10.1038/Sj.Cgt.7700885 |
0.555 |
|
| 2004 |
Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. The Prostate. 59: 370-82. PMID 15065085 DOI: 10.1002/Pros.20010 |
0.507 |
|
| 2004 |
Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. The Prostate. 59: 115-9. PMID 15042611 DOI: 10.1002/Pros.20059 |
0.507 |
|
| 2003 |
Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: A means for inhibition of the Tcf signaling axis Oncogene. 22: 5602-5613. PMID 12944908 DOI: 10.1038/Sj.Onc.1206802 |
0.458 |
|
| 2003 |
Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. The Biochemical Journal. 375: 373-83. PMID 12864730 DOI: 10.1042/Bj20030689 |
0.712 |
|
| 2003 |
Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Molecular Endocrinology (Baltimore, Md.). 17: 1484-507. PMID 12750453 DOI: 10.1210/Me.2003-0020 |
0.709 |
|
| 2003 |
Nelson CC, Hoffart D, Gleave ME, Rennie PS. Application of gene microarrays in the study of prostate cancer. Methods in Molecular Medicine. 81: 299-320. PMID 12725128 DOI: 10.1385/1-59259-372-0:299 |
0.517 |
|
| 2003 |
Yeung LH, Read JT, Sorenson P, Nelson CC, Jia W, Rennie PS. Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter. The Biochemical Journal. 371: 843-55. PMID 12540291 DOI: 10.1042/Bj20021816 |
0.567 |
|
| 2002 |
Rao MA, Cheng H, Quayle AN, Nishitani H, Nelson CC, Rennie PS. RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. The Journal of Biological Chemistry. 277: 48020-7. PMID 12361945 DOI: 10.1074/Jbc.M209741200 |
0.691 |
|
| 2002 |
He M, Rennie PS, Dragowska V, Nelson CC, Jia W. A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53. Febs Letters. 517: 151-4. PMID 12062426 DOI: 10.1016/S0014-5793(02)02609-1 |
0.32 |
|
| 2002 |
Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, Sesterhenn I. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1172-7. PMID 12006534 |
0.438 |
|
| 2002 |
Portigal CL, Cowell SP, Fedoruk MN, Butler CM, Rennie PS, Nelson CC. Polychlorinated biphenyls interfere with androgen-induced transcriptional activation and hormone binding. Toxicology and Applied Pharmacology. 179: 185-94. PMID 11906248 DOI: 10.1006/Taap.2002.9371 |
0.443 |
|
| 2002 |
Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. The Journal of Biological Chemistry. 277: 17933-43. PMID 11856748 DOI: 10.1074/Jbc.M200135200 |
0.378 |
|
| 2001 |
Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 58: 39-49. PMID 11502446 DOI: 10.1016/S0090-4295(01)01241-9 |
0.58 |
|
| 2001 |
Lareyre JJ, Reid K, Nelson C, Kasper S, Rennie PS, Orgebin-Crist MC, Matusik RJ. Characterization of an androgen-specific response region within the 5' flanking region of the murine epididymal retinoic acid binding protein gene. Biology of Reproduction. 63: 1881-92. PMID 11090461 DOI: 10.1095/Biolreprod63.6.1881 |
0.436 |
|
| 2000 |
Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology. 141: 2257-65. PMID 10830316 DOI: 10.1210/Endo.141.6.7520 |
0.495 |
|
| 2000 |
Nelson CC, Hendy SC, Shukin RJ, Cheng H, Bruchovsky N, Koop BF, Rennie PS. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Molecular Endocrinology (Baltimore, Md.). 13: 2090-107. PMID 10598584 DOI: 10.1210/Mend.13.12.0396 |
0.4 |
|
| 1999 |
Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Reviews. 17: 401-9. PMID 10453284 DOI: 10.1023/A:1006121219097 |
0.547 |
|
| 1999 |
Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shiu RP, Sheppard PC, Matusik RJ. Selective activation of the probasin androgen-responsive region by steroid hormones. Journal of Molecular Endocrinology. 22: 313-25. PMID 10343290 DOI: 10.1677/Jme.0.0220313 |
0.49 |
|
| 1998 |
Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Differential transactivation by the androgen receptor in prostate cancer cells. The Prostate. 36: 256-63. PMID 9719026 DOI: 10.1002/(Sici)1097-0045(19980901)36:4<256::Aid-Pros7>3.0.Co;2-D |
0.589 |
|
| 1998 |
Bai GE, Kasper S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A. Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells Journal of Andrology. 19: 127-135. PMID 9570735 DOI: 10.1002/J.1939-4640.1998.Tb01981.X |
0.593 |
|
| 1997 |
Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. The Journal of Biological Chemistry. 272: 17485-94. PMID 9211894 DOI: 10.1074/jbc.272.28.17485 |
0.445 |
|
| 1997 |
Akakura K, Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, Tenniswood M, Fox K. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. The Journal of Steroid Biochemistry and Molecular Biology. 59: 501-11. PMID 9010356 DOI: 10.1016/S0960-0760(96)00132-X |
0.404 |
|
| 1997 |
Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. The Journal of Steroid Biochemistry and Molecular Biology. 59: 397-404. PMID 9010345 DOI: 10.1016/S0960-0760(96)00125-2 |
0.468 |
|
| 1997 |
Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. The Journal of Steroid Biochemistry and Molecular Biology. 59: 243-50. PMID 9010316 DOI: 10.1016/S0960-0760(96)00116-1 |
0.507 |
|
| 1997 |
Bruchovsky N, Goldenberg SL, Gleave M, Rennie P, Akakura K, Sato N. Intermittent therapy for prostate cancer Endocrine-Related Cancer. 4: 153-177. DOI: 10.1677/Erc.0.0040153 |
0.533 |
|
| 1996 |
Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. The Journal of Steroid Biochemistry and Molecular Biology. 58: 139-46. PMID 8809195 DOI: 10.1016/0960-0760(96)00018-0 |
0.521 |
|
| 1995 |
Dubé JY, Chapdelaine P, Guerin S, Leclerc S, Rennie PS, Matusik RJ, Tremblay RR. Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. Journal of Andrology. 16: 304-311. DOI: 10.1002/J.1939-4640.1995.Tb00534.X |
0.495 |
|
| 1994 |
Rennie PS, Mawji NR, Coldman AJ, Godolphin W, Jones EC, Vielkind JR, Bruchovsky N. Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRPM-2, with survival in patients with breast cancer. Cancer. 72: 3648-54. PMID 8252481 DOI: 10.1002/1097-0142(19931215)72:12<3648::Aid-Cncr2820721216>3.0.Co;2-L |
0.311 |
|
| 1994 |
Rennie PS, Bruchovsky N, Akakura K, Goldenberg SL, Otal N, Akakura S, Wong P, Tenniswood M. Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma. The Journal of Steroid Biochemistry and Molecular Biology. 50: 31-40. PMID 8049130 DOI: 10.1016/0960-0760(94)90169-4 |
0.502 |
|
| 1993 |
Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Molecular Endocrinology (Baltimore, Md.). 7: 23-36. PMID 8446105 DOI: 10.1210/Mend.7.1.8446105 |
0.474 |
|
| 1993 |
Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer. 72: 1685-1691. PMID 7688656 DOI: 10.1002/1097-0142(19930901)72:5<1685::Aid-Cncr2820720532>3.0.Co;2-3 |
0.441 |
|
| 1993 |
Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 71: 2782-90. PMID 7682149 DOI: 10.1002/1097-0142(19930501)71:9<2782::Aid-Cncr2820710916>3.0.Co;2-Z |
0.461 |
|
| 1991 |
Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. The Journal of Steroid Biochemistry and Molecular Biology. 37: 843-7. PMID 2126735 DOI: 10.1016/0960-0760(90)90430-S |
0.348 |
|
| 1990 |
Freeman SN, Rennie PS, Chao J, Lund LR, Andreasen PA. Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats. The Biochemical Journal. 269: 189-93. PMID 2115769 DOI: 10.1042/Bj2690189 |
0.333 |
|
| 1989 |
Rennie PS, Bruchovsky N, Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate. American Journal of Clinical Oncology. S13-7. PMID 3071950 DOI: 10.1097/00000421-198801102-00004 |
0.531 |
|
| 1989 |
Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. The Journal of Urology. 140: 1460-5. PMID 2973529 DOI: 10.1016/S0022-5347(17)42073-8 |
0.455 |
|
| 1989 |
Rennie PS, Bowden JF, Freeman SN, Bruchovsky N, Cheng H, Lubahn DB, Wilson EM, French FS, Main L. Cortisol alters gene expression during involution of the rat ventral prostate Molecular Endocrinology. 3: 703-708. PMID 2498651 DOI: 10.1210/Mend-3-4-703 |
0.502 |
|
| 1989 |
Ho KC, Snoek R, Quarmby V, Viskochil DH, Rennie PS, Wilson EM, French FS, Bruchovsky N. Primary structure and androgen regulation of a 20-kilodalton protein specific to rat ventral prostate. Biochemistry. 28: 6367-73. PMID 2477055 DOI: 10.1021/Bi00441A032 |
0.392 |
|
| 1988 |
Rennie PS, Bowden JF, Bruchovsky N, Frenette PS, Foekens JA, Cheng H. DNA and protein components of nuclear acceptor sites for androgen receptors in the rat prostate. Journal of Steroid Biochemistry. 27: 513-20. PMID 3695493 DOI: 10.1016/0022-4731(87)90348-7 |
0.443 |
|
| 1988 |
Rennie PS, Bruchovsky N, Goldenberg SL, Lawson D, Fletcher T, Foekens JA. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate. The Journal of Urology. 139: 1337-42. PMID 2967378 DOI: 10.1016/S0022-5347(17)42914-4 |
0.445 |
|
| 1988 |
Rennie PS, Bowden JF, Bruchovsky N, Cheng H. The relationship between inhibition of plasminogen-activator activity and prostatic involution. The Biochemical Journal. 252: 759-64. PMID 2458715 DOI: 10.1042/Bj2520759 |
0.504 |
|
| 1988 |
Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, McLoughlin MG. Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. The Journal of Clinical Endocrinology and Metabolism. 67: 806-16. PMID 2458378 DOI: 10.1210/Jcem-67-4-806 |
0.454 |
|
| 1987 |
Bruchovsky N, Rennie PS, To MP, Snoek R, Lefebvre YA, Golsteyn EJ. Chemical demonstration of nuclear androgen receptor following affinity chromatography with immobilized ligands. The Prostate. 10: 207-22. PMID 3588412 DOI: 10.1002/Pros.2990100304 |
0.409 |
|
| 1987 |
Bruchovsky N, Goldenberg S, Rennie P, To M, Coppin C. 1 Mechanisms and effects of androgen withdrawal therapies Journal of Steroid Biochemistry. 28: 195. DOI: 10.1016/0022-4731(87)91631-1 |
0.332 |
|
| 1987 |
Lawson D, Bruchovsky N, Rennie P, Goldenberg S, Fletcher T. Relative effectiveness of androgen withdrawal therapies as measured by changes in the intracellular distributions of androgen receptors and dihydrotestosterone Journal of Steroid Biochemistry. 28: 11. DOI: 10.1016/0022-4731(87)91130-7 |
0.397 |
|
| 1986 |
Giles MG, Rennie PS, Bruchovsky N. Changes in endonuclease activity during growth and regression of the Shionogi mammary carcinoma. Molecular and Cellular Endocrinology. 45: 167-73. PMID 3011560 DOI: 10.1016/0303-7207(86)90144-9 |
0.383 |
|
| 1984 |
De Larminat MA, Bruchovsky N, Rennie PS, Lee SP, Tertzakian G. Synthesis and evaluation of immobilized androgens for affinity chromatography in the purification of nuclear androgen receptor. The Prostate. 5: 123-40. PMID 6709516 DOI: 10.1002/Pros.2990050202 |
0.369 |
|
| 1984 |
Rennie PS, Bouffard R, Bruchovsky N, Cheng H. Increased activity of plasminogen activators during involution of the rat ventral prostate. The Biochemical Journal. 221: 171-8. PMID 6431969 DOI: 10.1042/bj2210171 |
0.37 |
|
| 1984 |
De Larminat M, Bruchovsky N, Rennie P, Lee S, Tertzakian G. Synthesis and Evaluation of Immobilized Androgens for Affinity Chromatography in the Purification of Nuclear Androgen Receptor Journal of Urology. 132: 851-851. DOI: 10.1016/S0022-5347(17)49922-8 |
0.439 |
|
| 1983 |
Callaway TW, Bruchovsky N, Rennie PS, Comeau T. Mechanisms of action of androgens and antiandrogens: effects of antiandrogens on translocation of cytoplasmic androgen receptor and nuclear abundance of dihydrotestosterone. The Prostate. 3: 599-610. PMID 7155992 DOI: 10.1002/pros.2990030609 |
0.317 |
|
| 1983 |
Djøseland O, Bruchovsky N, Rennie PS, Otal N, Høglo S. 5 alpha-reductase activity in stroma and epithelium of rat prostate and epididymis. A contribution to elucidation of the mechanism for development of hyperplastic growth of prostatic tissue. Acta Endocrinologica. 103: 273-81. PMID 6190338 DOI: 10.1530/Acta.0.1030273 |
0.469 |
|
| 1983 |
Rennie PS, Bruchovsky N, Mo S, de Jong G, Cheng H. Plasminogen activator activity in human prostate and breast tumors: relationship to steroid receptors. The Prostate. 3: 483-92. PMID 6183652 DOI: 10.1002/Pros.2990030507 |
0.487 |
|
| 1983 |
Rennie PS, Bruchovsky N, McLoughlin MG, Batzold FH, Dunstan-Adams EE. Kinetic analysis of 5α-reductase isoenzymes in benign prostatic hyperplasia (BPH) Journal of Steroid Biochemistry. 19: 169-173. DOI: 10.1016/S0022-4731(83)80022-3 |
0.358 |
|
| 1983 |
Rennie P, Bruchovsky N, Cheng H, Foekens J. 391 Turnover of 3S androgen receptors bound to the nuclear matrix of prostatic nuclei Journal of Steroid Biochemistry. 19: 130. DOI: 10.1016/0022-4731(83)91891-5 |
0.51 |
|
| 1982 |
De Larminat MA, Rennie PS, Bruchovsky N. Radioimmunoassay measurements of nuclear dihydrotestosterone in rat prostate. Relationship to androgen receptors and androgen-regulated responses. The Biochemical Journal. 200: 465-74. PMID 7342963 DOI: 10.1042/Bj2000465 |
0.536 |
|
| 1982 |
Bruchovsky N, Rennie PS, Comeau T. Partial purification of nuclear androgen receptor by micrococcal nuclease digestion of chromatin and hydrophobic interaction chromatography. European Journal of Biochemistry. 120: 399-405. PMID 7318834 DOI: 10.1111/J.1432-1033.1981.Tb05717.X |
0.425 |
|
| 1982 |
de Larminat MA, Bruchovsky N, Rennie PS. Concentration and preservation of nuclear androgen receptor by lyophilisation. Journal of Steroid Biochemistry. 16: 811-6. PMID 7109583 DOI: 10.1016/0022-4731(82)90039-5 |
0.404 |
|
| 1982 |
Filipenko JD, Rennie PS, Bruchovsky N. The androgenic regulation of superhelical-DNA nicking-closing enzyme in rat ventral prostate. The Biochemical Journal. 196: 195-202. PMID 6272751 DOI: 10.1042/bj1960195 |
0.36 |
|
| 1980 |
Rennie PS, Bruchovsky N, Noble RL, Mo S. Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats Biochimica Et Biophysica Acta. 632: 428-436. PMID 7417531 DOI: 10.1016/0304-4165(80)90238-X |
0.491 |
|
| 1980 |
Rennie PS, Bruchovsky N, Noble RL, Mo S. Plasminogen activator in prostatic tumors of Nb rats Biochimica Et Biophysica Acta. 632: 437-443. PMID 6998504 DOI: 10.1016/0304-4165(80)90239-1 |
0.475 |
|
| 1980 |
Wilkin RP, Bruchovsky N, Shnitka TK, Rennie PS, Comeau TL. Stromal 5 alpha-reductase activity is elevated in benign prostatic hyperplasia. Acta Endocrinologica. 94: 284-8. PMID 6158242 DOI: 10.1530/Acta.0.0940284 |
0.427 |
|
| 1979 |
Bruchovsky N, Rennie P. 12. Hormone receptors in prostatic tissue Journal of Steroid Biochemistry. 11: xi-xii. DOI: 10.1016/0022-4731(79)90376-5 |
0.429 |
|
| 1978 |
Rennie PS, Bruchovsky N, Hook SL. Androgenic regulation of a tissue specific isoenzyme of acid phosphatase in rat ventral prostate. Journal of Steroid Biochemistry. 9: 585-93. PMID 692124 DOI: 10.1016/0022-4731(78)90167-X |
0.4 |
|
| 1978 |
Bruchovsky N, Rennie PS, Doorn EV, Noble RL. Pathological growth of androgensensitive tissues resulting from latent actions of steroid hormones. Journal of Toxicology and Environmental Health. 4: 391-408. PMID 351203 DOI: 10.1080/15287397809529667 |
0.331 |
|
| 1976 |
Rennie PS, Symes EK, Mainwaring WJ. The androgenic regulation of the activities of enzymes engaged in the synthesis of deoxyribonucleic acid in rat ventral prostate gland. The Biochemical Journal. 152: 1-16. PMID 1212219 DOI: 10.1042/bj1520001 |
0.433 |
|
| 1976 |
Mainwaring WI, Rennie PS, Keen J. The androgenic regulation of prostate proteins with a high affinity for deoxyribonucleic acid. Evidence for a prostate deoxyribonucleic acid-unwinding protein. The Biochemical Journal. 156: 253-64. PMID 942409 DOI: 10.1042/bj1560253 |
0.398 |
|
| 1975 |
Bruchovsky N, Rennie PS, Lesser B, Sutherland DJ. The influence of androgen receptors on the concentration of androgens in nuclei of hormone-responsive cells. Journal of Steroid Biochemistry. 6: 551-60. PMID 171504 DOI: 10.1016/0022-4731(75)90034-5 |
0.317 |
|
| 1975 |
Bruchovsky N, Rennie PS, Vanson A. Studies on the regulation of the concentration of androgens and androgen receptors in nuclei of prostatic cells. Biochimica Et Biophysica Acta. 394: 248-66. PMID 166692 DOI: 10.1016/0005-2736(75)90263-1 |
0.368 |
|
| Show low-probability matches. |